These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12032523

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [Abstract] [Full Text] [Related]

  • 3. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
    Fitzhugh CD, Wigfall DR, Ware RE.
    Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.
    Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC.
    Br J Haematol; 2008 Jan; 140(1):80-5. PubMed ID: 17991298
    [Abstract] [Full Text] [Related]

  • 5. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU.
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B, Neonato MG, Girot R, Aractingi S.
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

  • 14. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM, Howard TA, Zimmerman SA, Ware RE.
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyurea treatment of sickle cell anemia in hospital-based practices.
    Ferguson RP, Arun A, Carter C, Walker SD, Castro O.
    Am J Hematol; 2002 Aug; 70(4):326-8. PubMed ID: 12214583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.